Endothelin receptor antagonists will lead Eisenmenger complex management sales through 2036 with 41.3% of the drug type segment in 2026. Echocardiogram leads the diagnostic segment with a 26.7% share. The market is projected to reach USD 9.0 billion in 2026 and USD 14.75 billion by 2036, creating an incremental opportunity of USD 5.78 billion.